Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM: Standardization of Service Pricing for CN Surgical Robots Conducive to MEDBOT-B Commercialization Prospects
Recommend 3 Positive 3 Negative 2 |
||||
|
||||
|
China's National Healthcare Security Administration released on January 20 the Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial) and held a press briefing in Beijing, according to JPMorgan's report. JPMorgan believes these guidelines will have a structurally positive impact on the Chinese surgical robot market, since they will establish a consistent pricing path while promoting the industry's transition towards a value-oriented and tiered reimbursement model. The report highlighted MEDBOT-B (02252.HK)'s rally of about 15% on the day of the announcement amid the market's highly positive response, reflecting improved visibility of the company's reimbursement mechanism and a clearer commercialization path. JPMorgan has given MEDBOT-B an Overweight rating and a target price of HKD42. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
